Form 8-K Roivant Sciences Ltd. For: Jan 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
RBC Capital on Prometheus Biosciences Inc (RXDX): 'continue to see PRA023 with best-in-class potential in UC'
January 4, 2023 11:33 AM ESTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $111.00 price target on Prometheus Biosciences Inc (NASDAQ: RXDX).
The analyst comments "This morning, ROIV disclosed positive topline of their recently licensed TL1A antibody RVT-3101 from PFE (link) from the induction phase of the ph.IIb trial... More
Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'
January 4, 2023 9:36 AM ESTCredit Suisse analyst Martin Auster reiterated an Outperform rating and $142.00 price target on Prometheus Biosciences Inc (NASDAQ: RXDX)
The analyst comments "RVT-3101 Ph2b TUSCANY Results in UC: This morning, Roivant announced Ph2b data for its anti-TL1A, RVT-3101 (fka PF-06480605). Placebo-adjusted clinical remission (CR) across all doses evaluated (50mg, 250mg, and 450mg) was 21% (32% 3101 vs. 12% pbo) in all patients... More
Truist Securities on Roivant Sciences (ROIV): 'RVT-3101 looks competitive in UC with differentiated safety/efficacy profile'
January 4, 2023 9:35 AM ESTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $19.00 price target on Roivant Sciences (NASDAQ: ROIV)
The analyst comments "This morning, ROIV reported interim data from the induction period from its controlled Ph2b study evaluating RVT-3101, TL1A that it recently in-licensed... More
